Free Essay

Eli Lilly in India

In: Business and Management

Submitted By zrahman
Words 374
Pages 2
Strategic Planning for a Mature Mission
Complete one set of answers per group

Please answer each of the following questions as a group in 40 words or less, and submit your answers at the beginning of the class at which this will be discussed. In each question, you should compare your group’s current perceptions, beliefs and practices with those you had when you were planning the first year of the simulation. Each group should submit up to two pages.

1. How did your perception of the environment change?

Each hotel began operations with equal amount of start-up capital and resources. In first year, we were unprepared for ruinous competition and competitors’ fierce strategies. Now we are developing rigorous strategy to gradually improve overall performance and accomplish our goals.

2. How did your perception of the synergy of your real and simulated resources change?

People are now more actively and productively involved in the decision-making process as people started to know more about each other, and resources are now allocated more effectively on sales capacity and performance as each department manager are working together.

Now everyone is well acquainted with each other and more actively involved in the decision-making process. Resources are allocated more effectively on sales capacity and performances as each department manager are working together. Thus improving our Total Resource Effectiveness.

3. How and why did your values change?

4. How did your mission evolve?

5. How have the selection and perception of your goals changed?

6. How has the structure of your management group changed?

7. How have the modes of decision-making changed?

8. How have the frequency and methods of communication changed.

9. How have your practices to allocate resources (real and simulated) changed.

10. How have the human resource practices for your group members changed.

Instructions for the Second Report to Shareholders

Each group will have 7 minutes to present and explain its financial strategies for maximizing market capitalization for Years 4, 5 and especially 6. The report must therefore concentrate on the following: investments, share issuing, payment of dividends, taking on debt and repayment of debt, and acquisition of competitors (if applicable). Operational performance should be mentioned only briefly. Questions will follow the presentation.…...

Similar Documents

Premium Essay

Eli Lilly

...purchase of Eli Lilly common stock. We performed various analyses, which included strategy analysis, fundamental analysis, valuation, and risk assessment. Our absolute valuation calculation shows that Eli Lilly is slightly undervalued however; our relative valuation calculation shows that Eli Lilly is fairly valued. We decided to use the relative valuation recommendation because of the risk that is involved in the industry today. Current risk factors that are threatening Eli Lilly are the FDA approval process, patent expirations, pipeline concerns, the purchase of Imclone and how it will be integrated into the company, and finally the ongoing recession. Eli Lilly currently has drugs pending FDA approval, notably Effient, a blood-thinner. Effient’s approval has been delayed twice, and is currently going to be reviewed by a special committee within the FDA in 2009. Analysts believe that Effient can become the dominant drug used around the world grossing billions in revenue; however, the FDA has not approved it yet. Eli Lilly also has patents running out on several of its highest grossing drugs including Zyprexa, Cymbalta, and Gemzar between 2011 and 2013. These are Eli Lilly’s top three grossing drugs and the patent expiration will raise questions about their future pipeline after 2013, especially if Effient does not get approved. Overall with all these questions and risk factors we decided to go with our relative valuation, which shows us Eli Lilly is......

Words: 8055 - Pages: 33

Premium Essay

Eli Lilly Ranbaxy Jv

...Assignment 2 —Eli Lilly in India: Rethinking the Joint Venture Strategy Executive summary Eli Lilly entered the Indian market in a joint venture with Ranbaxy, in order to capitalize on increasingly favourable market conditions, low costs and to gain a foothold for entering other Asian markets. This move succeeded because of a commitment to values for the two partners, cooperation and excellent management. Ranbaxy smoothed the way with existing distribution networks, government contacts and local market knowledge. Lilly provided foreign expertise, competent managers and capital. The venture earned both firms significant advances in market share and earnings, and the relationship remained positive throughout. As the Indian economy has become increasingly liberalized and open to foreign investment, there is great potential in the market. Other foreign firms are entering the market, and as a well-established powerful player in the market Lilly no longer needs to use Ranbaxy as an intermediate. Lilly seeks continued, stable growth in the region and needs to consolidate and refocus its business in niche drugs to remain competitive in a changing global business environment. Ranbaxy wants to move away from generics to become a more internationalized and R&D based company like Lilly, but needs significant cash flow in order to grow abroad. Both firms are considering options for the future. Problem statement Eli Lilly-Ranbaxy, a joint venture in India......

Words: 1408 - Pages: 6

Free Essay

Eli Lilly

...4: ELI LILLY 1. Por lo que podemos observar viendo los resultados obtenidos por la joint-venture, podemos afirmar que sí que se llevó a cabo una buena estrategia al realizar la joint-venture entre Lilly y Ranbaxy, ya que la cuenta de resultados tanto de la empresa conjunta como las de ambas empresas por separado obtuvieron un incremento en sus beneficios, no solo obteniendo reducciones en los costes sino también aprovechándose de las buenas referencias que podían obtener de ambas empresas para combinarlas en la joint-venture, el buen conocimiento del mercado y la reputación en la india de Ranbaxy y la asociación “inconsciente” de calidad que generaban los productos extranjeros importados. Además la buena afinidad entre ambas empresas y el que supieran mantener en mente el objetivo común de ambas que era el buen funcionamiento de la joint-venture, fue un aliciente más en esta asociación. Debemos destacar también el que Eli Lilly omitiese la entrada en el mercado indio de aquellos productos a los que les convenía más la existencia de patentes de producto en lugar de las patentes de proceso (como por el ejemplo el Prozac) y de este modo evitar que otras productoras indias aprovechasen el lanzamiento de dicho producto para variar el proceso obteniendo el mismo producto, podríamos decir que hizo una buena gestión evitando lanzarse piedras a su propio tejado. 2. ( )=retos únicos Andrew Mascarenhas: supo darse cuenta de la necesidad de incluir el nombre de “Eli Lilly”......

Words: 1122 - Pages: 5

Premium Essay

Eli Lilly

...Eli Lilly Eli Lilly was founded in 1876 and started off as a small pharmaceutical manufacturer. The company has grown to be one of the biggest pharmaceutical manufacturers in the world. In the 1980’s their number one product was Prozac, and right behind that was insulin. Eli Lilly invested over $700 million dollars of research and development money into improving the lives and health of diabetic patients. There are two types of diabetes, Type I, and Type II. Type I or juvenile, is typically diagnosed in children or young adults. Diabetic children are not able to produce insulin on their own, therefore, they must have insulin injections daily. In 1921 there was no effective treatment for Type I diabetes and patients were only expected to live one year after diagnosis. Type II diabetes is the most common form of this disease and is general caused by obesity and can happen at any age. With Type II, the body does not use insulin properly, so it tries to compensate, but blood glucose levels become irregular. When first diagnosed with Type II, most patients take an oral dose of medication to help regulate insulin levels, as the disease progresses it usually necessitates insulin injections. In 1995 Europe and North America accounted for 80% of the world’s insulin market. The high rate of diagnosis in the United States and Europe was due to the higher than average incidence of obesity. Approximately 2% of the world’s......

Words: 1399 - Pages: 6

Premium Essay

Eli Lilly

...Question1: Did Eli Lilly pursue the right strategy to enter the Indian market? In 1993 Eli Lilly, one of the leading pharmaceutical firms in the USA, started a joint venture in India with the leading Indian company Ranbaxy. The decision was dictated by the conditions of the US market and opportunities of the Indian market. Costlier manufacturing practices due to strict governmental control, soaring prices in 1990s, invasion of cheap generics to the USA market as opposed to low costs in India and new regulations that opened Indian market to foreign investments (up to 51%) created tempting conditions to enter one of the emerging huge markets of the world. Alliance with Ranbaxy was a smart strategy for Eli Lilly to establish its presence in India. Ranbaxy was the second largest manufacturing company of bulk drugs and generics with domestic market share of 15% in India with established distribution network and the second largest exporter to different countries, including Russia (which Eli Lilly was attempting to reach), with capital cost 50-75% lower than those of comparable US plant and R&D expenses of 2-5% of sales. Besides, Ranbaxy developed its own process for Eli Lilly's patented drug Cefaclor. Since Eli Lilly's product patent for Cefaclor expired in 1992 and the firm was expecting to protect its monopoly with process patents which were due to expire only in 1994, this gave great scope for a mutually advantageous agreement between the two companies. There was also......

Words: 960 - Pages: 4

Premium Essay

Eli Lilly

...MANAGEMENT OF TECHNOLOGY Case Brief on Eli Lilly: The Evista Project TIMELINE 4000-2000 BC – Ancient Egyptians developed compresses around Skull to stop migraines. 1876 – Eli Lilly founded in Indianapolis, Indiana by Colonel Eli Lilly. 1970s – Early research in Lilly on Serotonin. 1988 – Prozac launched to market 1991 – Serotonin “1f” receptor cloned by Lilly’s collaborator, Synaptic Pharmaceutical Corporation. CNS group starts screening serotonin like compounds from Lilly’s historical library 1992 – Glaxo launched sumatriptin (Imitrex) 1994 March/April “Hot” lead compound found from the screen with good fit at the serotonin 1f receptor Kaldor gives combinatorial chemistry seminar to an in-house audience at Lilly March/June Improvement upon this lead made using traditional chemistry September Sphinx acquired December Schaus presents seminar on his research to other CNS research group leaders 1995 – PTAC(Project Approval Committee) meets to discuss strategic choices in migraine project 2001 – Projected launch, if approved, of Lilly’s migraine product 2003 - Patent protection of Prozac ends What is a heavyweight project team and how does it differ from a traditional approach used for organizing development projects at Eli Lilly? A functional structure is a traditional approach found in most mature and larger companies where people are grouped in disciplines that work under a sub-function manager. The different subfunctions coordinate ideas through detailed......

Words: 1655 - Pages: 7

Premium Essay

Eli Lilly and Ranbuxy

...ELI LILLY IN INDIA RETHINKING THE JOINT VENTURE STRATEGY Abhay Kishore – 01 Abhishek Kunal – 05 Anil Kumar Jadli – 11 J.Harish – 25 Khushal Malik – 28 Sharad Singh – 49 PHARMACEUTICAL INDUSTRY – Global Trend • • • • Mainly concentrated in the United States, Europe, and Japan Developing a drug from discovery to launch took 10 to 12 years. Cost of development of drug is between $500-$800 million. Drugs were strictly controlled by government agencies: o o o o Food and Drug Administration (FDA) – USA, CPMP – Europe 12% 8% North America Europe 38% 18% Asia Japan MHW – Japan DPCO & Indian Patent Act - India • • Size of industry : USD 960 billion in 2012. Few Firms control entire market (Oligopoly). 24% ROW • 4 Firms – Control 20% , • 20 Firms – 50-60%, • 50 Firms – 65-75% PHARMACEUTICAL INDUSTRY – Global Trend • Covered the chemical substance itself • Offered typically 20 years of protection • Usually a lag time of 1012 years by the time the patent was obtained and the launch date • Covered the method of processing or manufacturing the product • Very little protection because it was easy to slightly modify the process Global Issues in Pharma Sector • Prices in of the drugs varied in developed countries • US & Canada by factor 1.2 to 2.5. • Europe by factor 1.1 to 2.5. Parallel Trade: an outside company sells a patented product in a market not designated to sell the drug. o • Independent firm exploited parallel trade by using the......

Words: 2071 - Pages: 9

Premium Essay

Eli Lilly Ratio Analysis

...to compute and a write a summary (max. 250 words) interpreting selected liquidity ratios. 1. Companies Last name begins with the letters A through M:   CVS N through Z: Eli Lilly You can work individually or in a group of not more than 2.  If you work in a group, you must choose the members, and both must send the Academic Coach, Ms. Linda Anderson, a message stating so, AND the name of the member who would submit the assignment.  THE SUBMISSION FROM THE DESIGNATED MEMBER ALONE WILL BE GRADED.  If your last names fall in both categories (eg. Anderson and Surysekar), your message to Ms. Anderson should also include your choice of the company (CVS or Eli Lilly).  If group work, both members will get the same score for this assignment. 2. Ratios to compute and interpret (only the following 4 liquidity ratios, defined in page 704 of the text):           Current ratio           Current cash debt coverage ratio           Inventory turnover           Accounts receivable turnover   3.  Time period: Years 2009, 2010, 2011 4. Source: Company annual report CVS http://media.corporate-ir.net/media_files/IROL/99/99533/CVSCaremark2011_AR.pdf http://media.corporate-ir.net/media_files/irol/99/99533/2010_Annual_Report.pdf http://investors.cvscaremark.com/~/media/Files/C/CVS-IR/reports/cvs-ar-2009.pdf Eli......

Words: 491 - Pages: 2

Free Essay

Eli Lilly Case

...Eli Lilly is a leading pharmaceutical company located in Indianapolis, Indiana, which specializes in treatment of several high profile diseases. Evista, a newly developed drug by Eli Lilly, is an estrogen replacement therapy medicine for prevention of osteoporosis which through testing has seemed to lower the incidence of breast cancer in women. This FDA approved drug is expected to be a potential blockbuster and generate revenue of 1 billion US dollars per year for the company. Pharmaceuticals is a highly competitive market and it is imperative for the leading companies to recuperate their development costs and generate returns for stockholders as well as fund research and development for potential new drugs at almost a constant rate. With the profitable lifetime for drugs, in United States, being significantly shortened since the 1980’s, Lilly Research Laboratories was able to develop Evista in a much shorter time period by adopting a Matrix-Based development approach and utilizing heavyweight teams. This strayed from their usual path of function-based product development strategy. With the possibility of profound profits from the commercialization of Evista, Dr. Gus Watanabe has to weigh whether the increasing internal resistance to heavyweight teams and shortage of resources is worth it. Watanabe needs to make a decision about adopting this new successful heavyweight team approach for commercialization of Evista as well as product development. Changes in the past few......

Words: 2988 - Pages: 12

Premium Essay

Eli Lilly in India: Rethinking the Joint Venture Strategy

...ADMN417 Assignment 2: Eli Lilly in India: Rethinking the Joint Venture Strategy Executive summary: Eli Lilly entered into a joint venture with Ranbaxy in India in 1992. A decade later both must decide whether this relationship remains mutual beneficial. Both companies have enjoyed a strong working relationship with identical value system as well as strong growth. Ranbaxy has become international and thus needs to concentrate more on generics and growth in US and UK; the joint venture with Eli Lilly no longer seems to be central to Ranbaxy’s current goals. With major changes in India’s regulation and patent protection, Eli Lilly can now enter the Indian market independently and soon would enjoy product patent protection. Dr. Lorenzo Tallarigo, president of Intercontinental Operations at Eli Lilly should end the joint venture with Ranbaxy in India. Eli Lilly will purchase all outstanding shares held by Ranbaxy at a fair market value, rebrand its name in India to simply Eli Lilly, and maintain current staff from the joint venture. The current operation from the previous joint venture should be maintained without any additional major changes since profits are already assured beyond 2005. Ranbaxy will be able to focus on the international markets with additional capital and Eli Lilly to continue growth in India. Problem statement: A decade after the formation of the joint venture, several changes have occurred in both the external environment as well as the expectation......

Words: 1482 - Pages: 6

Premium Essay

Eli Lilly

...Reading 5-3: Hansen and Nohria (2004), How to build collaborative advantage Further Readings: 5 (UC) 6 (MY) BMAN70012-201415-MM-syllabus-v20150209 // Last Update: Mon Feb 23, 2015 // NS Multinational Management (MSc IBM) - Page 5/9 7 (UC, NS) 8 (UC, NS) 9 (UC, NS) 10 (UC, NS)  Birkinshaw & Hood (2001), Danneels (2002), March (1991) Case Presentation and discussion:  Case 1: Mahindra & Mahindra in South Africa (Ch 1)  Case 2: The Globalization of CEMEX (Ch 2) Case Presentation and discussion:  Case 3: A Speed Race: Benelli & QJ (Ch 2)  Case 4: GE’s imagination breakthroughs: The Evo project (Ch 3) Case Presentation and discussion:  Case 5: McKinsey & Company (Ch 5) Case Presentation and discussion:  Case 6: Eli Lily in India (Ch 6)  Case 7: ECCO A/S Global value chain management (Ch 4) 8 Group Case Projects Each group will develop and deliver a presentation that critically examines one of the cases scheduled from session 7- 10. 8.1   Presentation (PG) /Discussion Group (DG=otherwise) scheme: See schedule outlined below Contributions: 1 presentation per group (indicated by “*”) and 1 report per group. o Presentation Group: present case and initiate discussion in class (submit note page of your slides or other presentation material to course coordinator) o Discussion Group (DG): engage in critical discussions and submit discussant report evaluating the case report of the assigned presentation group Group Case 1 Case 2 Case 3 Case 4 Case 5......

Words: 3318 - Pages: 14

Premium Essay

Case 6-3 Eli Lilly in India

...CASE 6-3 “Eli Lilly in India: Rethinking the Joint Venture Strategy” 1. I think Eli Lilly pursued the right strategy joining Ranbaxy Laboratories to enter the Indian market. While companies were using the global market to amortize the huge investments required to produce a new drug, they were hesitant to invest in countries where the intellectual property regime was weak. During the 1990s both companies had a strong reason for the joint venture. Ranbaxy wanted to make its presence globally and Lilly wanted to get their feet on Indian grounds. In 1992, Ranbaxy approached Lilly to investigate the possibility of supplying certain active ingredients or sourcing of intermediate products to Lilly in order to provide low cost sources of intermediate pharmaceutical ingredients. Based on the strategic alliance, Ranbaxy would supply certain products to the joint venture from its own portfolio that were currently being manufactured in India and then formulate and finish some of Lily’s products locally. From the beginning, both companies had a lot in common, they both believed in high ethical standards, technology and innovation, and future of patented products. They created the joint venture with $7.1 million capital and an initial subscribed equity capital of $3 million, with equal contribution from Lilly and Ranbaxy, leading to an equity ownership of 50 percent each. India, with an 800 million population had about 300 million of people that were considered to...

Words: 855 - Pages: 4

Premium Essay

Eli Lilly in India Rethinking the Joint Venture Strategy

...Eli Lilly in India: Rethinking the Joint Venture Strategy To: Dr. Lorenzo Tallarigo, President of Intercontinental Operations From: Senior Operations Director Re: Strategic direction for joint venture between Eli Lilly Co and Ranbaxy Laboratories Limited Problem After enjoying a successful JV partnership with Ranbaxy for the last few years, the strategic decision that Lilly now has to make is how to move forward. The Indian pharmaceutical industry has witnessed some significant changes and it seems that the business goals of both companies have diverged as well. Situation Overview Thus far it appears that Eli Lilly’s decision to enter the Indian market has been a wise one. It has enjoyed a successful partnership with Ranbaxy, which has also allowed its brands to gain recognition within the local market. Considering other metrics, including sales growth, access to new distributors and innovative product development, the JV has proven to be successful as well. Both parties agree that the JV has proven mutually beneficial, however circumstances have changed considerably since the venture was first initiated. Ranbaxy has expanded its own operations internationally and expanded its global reach through various acquisitions. In addition, the business strategies of both firms have taken a divergent direction. Lilly would like to continue to focus on the development of its patented global drugs, through innovation and discovery. On the other hand, Ranbaxy believes that its...

Words: 1871 - Pages: 8

Premium Essay

Case Analysis: Eli Lilly in India:

...1. Did Eli Lilly pursue the right strategy (i.e., should it have used a joint venture) to enter the Indian market? Why or why not? You should refer to Chapter 6 of the notes for guidance. With the upward trend of globalization, cross-border commercialization has become inherent in business strategies pursuing not only improved competitiveness but to avoid market share erosion. Expanding to new markets, reducing friction with socio-cultural and legal barriers, reduce capital costs, securing raw materials and implementing economies of scale are just a few motivations which to look abroad for and consider the intricacies of operating in another country. Changes in India’s economic policies from an import substitution to an export-driven one, was the legal foundation that allowed Eli Lilly to pursue its interest to market its drugs in India, where it already had relationships with local manufacturers to produce human or animal insulin for the Soviet Union market, but did not for the Indian market (Bartlett & Beamish, 2014, p. 524) The opportunity presented by Ranbaxy, the second largest pharmaceutical company in India, to supply certain active ingredients or intermediate products to formulate and complete Lilly’s, and for the Joint Venture (JV) to sell and distribute those products, was the perfect opportunity to enter a “new” market while sharing the costs and risks with a well-known and respected partner. With the then existing market conditions (Sales turnover caps,......

Words: 863 - Pages: 4

Premium Essay

Eli Lilly Case Study

...University of Maryland Case Study Analysis Eli Lilly: Developing Cymbalta Case Study AMBA 650 Section 1131 Kelvin Harris January 24, 2012 Executive Summary Eli Lilly and Company resounding success was the arrival of Prozac in 1988. By mid-1988, a new anti-depressant team was formed to find and develop a drug that would be the successor to Prozac. The strategic issues and problems they faced were developing a new drug to replace Prozac, meeting the company budget constraints to perform clinical trials, and finally launch the new drug by mid-2001. The analysis and evaluation revealed that the pharmaceutical industry is changing fast and it usually takes a long time and millions of dollars to develop a new drug. The recommendation for Eli Lilly is to take the lead in developing the new drug Cymbalta, invest a stable share of the company revenue, seek the FDA approval for the development of Cymbalta before going to market, and not change their market plan from the FDA approved Cymbalta dosage of 20 mg twice daily. Introduction Eli Lilly and Company was founded by Colonel Eli Lilly, Lilly’s namesake, in 1876 when he purchased a laboratory on Pearl Street in Indianapolis, Indiana. Eli Lilly was a pharmacist who had served in the Union Army during the Civil War. The company success included creating the process for applying gelatin-coating to pills for easier swallowing and the introduction of Iletin which was the first mass-produced insulin. ......

Words: 1938 - Pages: 8